Evotec Forms Oncology Research Pact with Plectonic for Next-Gen T-Cell Therapies
EVO is trading near its 52-week low of $1.8 (0.0% above the low).
Summary
Evotec and Plectonic Biotech announced a research collaboration to develop next-generation T-cell-engaging approaches for solid tumors. This partnership combines Evotec's BiTco platform with Plectonic's LOGIBODY® technology, aiming to enhance precision and potency in a challenging oncology area. The news provides a positive strategic development for Evotec, following a period of significant financial setbacks including a substantial H1 net loss and reduced full-year guidance. The collaboration is currently focused on generating preclinical proof-of-concept data.
At the time of this announcement, EVO was trading at $1.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $670M. The 52-week trading range was $1.80 to $4.27. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.